ProNAi has developed a novel, patent-protected technology, called DNAi, to attack cancer and prolong survival by turning off cancer genes at their source with a small piece of DNA (also called an oligo) delivered in a fatty particle. DNAi is part of an exciting new class of “gene-silencing” drugs, but is unlike the other approaches which target RNA, a downstream product of DNA. ProNAi’s lead drug PNT2258 is specifically designed to treat cancers that overexpress BCL2.
ProNAi has advanced its first drug candidate, PNT2258, into Phase II clinical development. The company’s lead product candidate, PNT2258, has demonstrated in vivo efficacy in human tumor xenograft models. Abstracts and presentations of the clinical results for PNT2258 are available upon request.
Since ProNAi was established in May 2004, the company has made rapid and substantial progress in advancing its first product candidate. The company has:
- Advanced PNT2258, its lead drug product candidate, from discovery to IND-enabling studies in 24 months. Preclinical studies have demonstrated striking synergistic activity with Rituxan® (rituxumab) in a Rituxan-resistant xenograft model of non-Hodgkin’s Lymphoma (NHL) and activity with Taxotere® (docetaxel) in models of hormone resistant prostate cancer and melanoma.
- Developed a proprietary product formulation and an efficient GMP manufacturing process for PNT2258 to support its entry into clinical trials.
- Identified follow-on products against frequently aberrant oncogenes. The table below highlights ProNAi’s current pipeline of products:
The table below highlights a select list of pipeline products. Please contact Business Development for a complete list of DNAi oligonucleotides designed to priority targets.